Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE-Reference-Cited by-同舟云学术

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

Published:2020-07-21 Issue:4 Volume:35 Page:1134-1144
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Goldschmidt Hartmut^ORCID,Baertsch Marc-Andrea^ORCID,Schlenzka Jana,Becker Natalia,Habermehl Christina,Hielscher Thomas,Raab Marc-Steffen,Hillengass Jens,Sauer Sandra,Müller-Tidow Carsten^ORCID,Luntz Steffen,Jauch Anna,Hose Dirk,Seckinger Anja,Brossart Peter,Goerner Martin,Klein Stefan,Schmidt-Hieber Martin,Reimer Peter,Graeven Ullrich,Fenk Roland,Haenel Mathias,Martin Hans,Lindemann Hans W.,Scheid Christoph,Nogai Axel,Salwender Hans,Noppeney Richard,Besemer Britta,Weisel Katja,

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-020-0948-0.pdf

Reference28 articles.

1. Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, et al. From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives. Haematologica. 2017;103:197-211.

2. Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, et al. Multiple myeloma, version 3.2017, NCCN Clinical Practice Guidelines in oncology. J Natl Compr Canc Netw. 2017;15:230–69.

3. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996;335:91–7.

4. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–83.

5. Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–20.

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Continued need for autologous transplantation in relapsed myeloma;The Lancet Haematology;2024-09

2. Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial;The Lancet Haematology;2024-09

3. Effects of Consolidation Therapy With Autologous Hematopoietic Stem Cell Transplantation After BCMA-CAR T-Cell Therapy on the Survival of Patients With Relapsed or Refractory Multiple Myeloma;Transplantation and Cellular Therapy;2024-09

4. Impact of second autologous stem‐cell transplantation at relapsed multiple myeloma: A French multicentric real‐life study;HemaSphere;2024-07-29

5. Intensive salvage chemotherapy with VDTPACE or mCBAD followed by hematopoietic stem‐cell support for refractory/relapsed multiple myeloma;European Journal of Haematology;2024-06-18